Nasal Spray Study in Sjogren's Dry Eye Disease

NCT ID: NCT05700422

Last Updated: 2024-11-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 39 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-05-01
• Study Completion Date: 2023-08-31

Brief Summary

This study will investigate how well OC-01 (varenicline) nasal spray can treat the signs and symptoms of dry eye disease in those Sjogren's Syndrome. Patients at least 18 years old with moderate-to-severe Sjogren's dry eye disease may be eligible for this study. If you are eligible to participate in the study and you decide to join, there will be 3 study visits over approximately 1 month. You will also self-administer the nasal spray at home every day, 2 times a day during this month.

Conditions

Sjogren's Syndrome; Dry Eye

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

OC-01 (varenicline solution) 0.03 mg nasal spray

Group Type: EXPERIMENTAL

Varenicline Nasal Spray

Intervention Type: DRUG

OC-01 (varenicline solution) 0.03 mg nasal spray

Interventions

Varenicline Nasal Spray

OC-01 (varenicline solution) 0.03 mg nasal spray

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Provide signed written consent prior to study-related procedures
• Be at least 18 years of age at the screening visit
• Have diagnosed moderate to severe Sjogrens Syndrome via blood work or biopsy Category 2 staining score for Conjunctiva based on the Van Bjisterveld and Utrect scale and 3 staining score for cornea based on the NEI scale
• Have been using Cyclosporine or Lifitegrast 3 months
• Be literate and able to complete questionnaires independently
• Be able and willing to use the study drug and participate in all study assessments and visits
• Have sufficient hand strength, in the opinion of the Investigator, to be able to independently administer the study drug
• Have provided verbal and written informed consent
• If a female is of childbearing potential, they must: use an acceptable means of birth control (acceptable methods of contraception include: hormonal oral, implantable, injectable, or transdermal contraceptives, mechanical spermicide in conjunction with a barrier such as a diaphragm or condom, IUD, or surgical sterilization of partner), and have a negative urine pregnancy test on Day 1

Exclusion Criteria

Have undergone previous ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgical procedure)

• Have had thermal pulsation or IPL in prior 3 months
• Have used topical ophthalmic corticosteroid therapy in prior 4 weeks
• Have had cataract surgery in the last 6 months
• Have clinically significant ocular trauma.
• Have active ocular Herpes simplex or Herpes Zoster infection
• Have ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at the discretion of the investigator.
• Have ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye).
• Have retinal pathology that can limit visual potential and refractive outcomes in the opinion of the investigator
• Have severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
• Have eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis).
• Have ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity).
• Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
• Have chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the Investigator, may lead to clinically significant risk of increased bleeding.
• Have had nasal or sinus surgery (including history of application of nasal cautery) or significant trauma to these areas
• Be currently treated with nasal continuous positive airway pressure
• Have any untreated nasal infection at Visit 1
• Have a vascularized polyp, severely deviated septum, chronic recurrent nosebleeds, or severe nasal obstruction as confirmed by intranasal examination performed at Visit 1.
• Have a known hypersensitivity to any of the procedural agents or study drug components
• Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1 and during the treatment period.
• Be a female who is pregnant, nursing, or planning a pregnancy at Visit 1. Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal oral, implantable, injectable, or transdermal contraceptives; mechanical spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. The risks of OC-01 among pregnant patients are not known.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Oyster Point Pharma, Inc.

INDUSTRY

Sponsor Role: collaborator

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Giacomina Massaro-Giordano

Clinician, Co-Director, Penn Dry Eye & Ocular Surface Center, and Professor of Clinical Ophthalmology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Scheie Eye Institute at the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Countries

United States

References

Gupta AS, Linaburg TJ, Iacobucci E, Augello PA, Qin VL, Ying GS, Bunya VY, Massaro M. Varenicline Solution Nasal Spray for the Treatment of Dry Eye Disease in Sjogren's Disease: A Pilot Study. Clin Ophthalmol. 2025 Mar 27;19:1073-1084. doi: 10.2147/OPTH.S512364. eCollection 2025.

Reference Type: DERIVED

PMID: 40166690 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

851655

Identifier Type: -

Identifier Source: org_study_id